Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carmen Fava

Showing results (1-10 of 116) with videos related to

Pageof 12
Sort By:
Seminars in Hematology|September 30, 2010
Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?Carmen Fava, Giuseppe Saglio
Blood|February 13, 2016
BCR-ABL1 mutation ≠ ponatinib resistanceGiuseppe Saglio, Carmen Fava
Journal of the National Comprehensive Cancer Network : JNCCN|January 7, 2012
Practical monitoring of chronic myelogenous leukemia: when to change treatmentGiuseppe Saglio, Carmen Fava
American Journal of Hematology|July 11, 2008
Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemiaCarmen Fava, Jorge Cortes
Clinical Advances in Hematology & Oncology : H&O|June 8, 2017
The biology of CML supports second-generation TKIs as frontline treatmentCarmen Fava, Giuseppe Saglio
Leukemia & Lymphoma|September 17, 2009
Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemiaGiuseppe Saglio, Carmen Fava
Seminars in Hematology|July 23, 2009
Optimizing first-line therapy for patients with chronic myeloid leukemiaCarmen Fava, Jorge Cortes
The Lancet. Oncology|April 17, 2016
Ponatinib for chronic myeloid leukaemia: future perspectivesCarmen Fava, Giuseppe Saglio
Current Hematologic Malignancy Reports|April 30, 2015
Milestones and monitoringAlessandro Morotti, Carmen Fava, Giuseppe Saglio
Clinical Lymphoma, Myeloma & Leukemia|January 31, 2012
Molecular resistance: an early indicator for treatment change?Carmen Fava, Hagop Kantarjian, Jorge Cortes
Pageof 12

Showing results (1-10 of 116) with videos related to

Sort By:
Pageof 12
Seminars in Hematology|September 30, 2010
Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?Carmen Fava, Giuseppe Saglio
Blood|February 13, 2016
BCR-ABL1 mutation ≠ ponatinib resistanceGiuseppe Saglio, Carmen Fava
Journal of the National Comprehensive Cancer Network : JNCCN|January 7, 2012
Practical monitoring of chronic myelogenous leukemia: when to change treatmentGiuseppe Saglio, Carmen Fava
American Journal of Hematology|July 11, 2008
Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemiaCarmen Fava, Jorge Cortes
Clinical Advances in Hematology & Oncology : H&O|June 8, 2017
The biology of CML supports second-generation TKIs as frontline treatmentCarmen Fava, Giuseppe Saglio
Leukemia & Lymphoma|September 17, 2009
Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemiaGiuseppe Saglio, Carmen Fava
Seminars in Hematology|July 23, 2009
Optimizing first-line therapy for patients with chronic myeloid leukemiaCarmen Fava, Jorge Cortes
The Lancet. Oncology|April 17, 2016
Ponatinib for chronic myeloid leukaemia: future perspectivesCarmen Fava, Giuseppe Saglio
Current Hematologic Malignancy Reports|April 30, 2015
Milestones and monitoringAlessandro Morotti, Carmen Fava, Giuseppe Saglio
Clinical Lymphoma, Myeloma & Leukemia|January 31, 2012
Molecular resistance: an early indicator for treatment change?Carmen Fava, Hagop Kantarjian, Jorge Cortes
Pageof 12